The novel prognostic marker, EHMT2, is involved in cell proliferation via HSPD1 regulation in breast cancer

Kim,Seon‑Kyu; Kim,Kwangho; Ryu,Jea‑Woon; Ryu,Tae‑Young; Lim,Jung Hwa; Oh,Jung‑Hwa; Min,Jeong‑Ki; Jung,Cho‑Rok; Hamamoto,Ryuji; Son,Mi‑Young; Kim,Dae‑Soo; Cho,Hyun‑Soo

doi:10.3892/ijo.2018.4608

The novel prognostic marker, EHMT2, is involved in cell proliferation via HSPD1 regulation in breast cancer

Authors:
- Seon‑Kyu Kim
- Kwangho Kim
- Jea‑Woon Ryu
- Tae‑Young Ryu
- Jung Hwa Lim
- Jung‑Hwa Oh
- Jeong‑Ki Min
- Cho‑Rok Jung
- Ryuji Hamamoto
- Mi‑Young Son
- Dae‑Soo Kim
- Hyun‑Soo Cho
View Affiliations

Affiliations: Korea Research Institute of Bioscience and Biotechnology, Daejeon 305‑333, Republic of Korea, Korea Institute of Toxicology (KIT), Daejeon 34114, Republic of Korea, Division of Molecular Modification and Cancer Biology, National Cancer Center, Tokyo 104‑0045, Japan
Published online on: October 26, 2018 https://doi.org/10.3892/ijo.2018.4608
Pages: 65-76
Copyright: © Kim et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Molecular classifications of breast cancer (BRC), such as human epidermal growth factor receptor 2 (HER2), luminal A and luminal B, have been developed to reduce unnecessary treatment by dividing patients with BRC into low‑ and high‑risk progression groups. However, these methods do not cover all of the pathological characteristics of BRC, and investigations into novel prognostic/therapeutic markers are thus continually required. In this study, we identified the overexpression of the histone methyltransferase, euchromatic histone‑lysine N‑methyltransferase 2 (EHMT2) in BRC samples (n=1,222) and normal samples (n=113) derived from the TCGA portal by performing a BRC tissue microarray. EHMT2 overexpression was clearly associated with a poor prognosis in multiple cohorts of patients with BRC (total, n=1,644). Furthermore, the knockdown of EHMT2 expression affected cell apoptosis via the downregulation and re‑localization of heat shock protein family D (Hsp60) member 1 (HSPD1). In addition, a statistically significant positive correlation between EHMT2 and HSPD1 expression was revealed in the clinical cohorts. On the whole, the findings of this study may assist the development of novel therapeutic strategies and provide a prognostic marker (EHMT2) for patients with BRC.

View Figures

View References

1	Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
2	Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
3	Pasculli B, Barbano R and Parrella P: Epigenetics of breast cancer: Biology and clinical implication in the era of precision medicine. Semin Cancer Biol. 51:22–35. 2018. View Article : Google Scholar : PubMed/NCBI
4	Jovanovic J, Rønneberg JA, Tost J and Kristensen V: The epigenetics of breast cancer. Mol Oncol. 4:242–254. 2010. View Article : Google Scholar : PubMed/NCBI
5	Messier TL, Gordon JA, Boyd JR, Tye CE, Browne G, Stein JL, Lian JB and Stein GS: Histone H3 lysine 4 acetylation and methylation dynamics define breast cancer subtypes. Oncotarget. 7:5094–5109. 2016. View Article : Google Scholar : PubMed/NCBI
6	Tachibana M, Sugimoto K, Fukushima T and Shinkai Y: Set domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3. J Biol Chem. 276:25309–25317. 2001. View Article : Google Scholar : PubMed/NCBI
7	Kim K, Son MY, Jung CR, Kim DS and Cho HS: EHMT2 is a metastasis regulator in breast cancer. Biochem Biophys Res Commun. 496:758–762. 2018. View Article : Google Scholar : PubMed/NCBI
8	Wang YF, Zhang J, Su Y, Shen YY, Jiang DX, Hou YY, Geng MY, Ding J and Chen Y: G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin. Nat Commun. 8:2742017. View Article : Google Scholar : PubMed/NCBI
9	Park SE, Yi HJ, Suh N, Park YY, Koh JY, Jeong SY, Cho DH, Kim CS and Hwang JJ: Inhibition of EHMT2/G9a epigenetically increases the transcription of Beclin-1 via an increase in ROS and activation of NF-κB. Oncotarget. 7:39796–39808. 2016.PubMed/NCBI
10	Lee JY, Lee SH, Heo SH, Kim KS, Kim C, Kim DK, Ko JJ and Park KS: Novel Function of Lysine Methyltransferase G9a in the Regulation of Sox2 Protein Stability. PLoS One. 10:e01411182015. View Article : Google Scholar : PubMed/NCBI
11	Miura S, Maesawa C, Shibazaki M, Yasuhira S, Kasai S, Tsunoda K, Maeda F, Takahashi K, Akasaka T and Masuda T: Immunohistochemistry for histone h3 lysine 9 methyltransferase and demethylase proteins in human melanomas. Am J Dermatopathol. 36:211–216. 2014. View Article : Google Scholar : PubMed/NCBI
12	Zhong X, Chen X, Guan X, Zhang H, Ma Y, Zhang S, Wang E, Zhang L and Han Y: Overexpression of G9a and MCM7 in oesophageal squamous cell carcinoma is associated with poor prognosis. Histopathology. 66:192–200. 2015. View Article : Google Scholar
13	Chandra D, Choy G and Tang DG: Cytosolic accumulation of HSP60 during apoptosis with or without apparent mitochondrial release: Evidence that its pro-apoptotic or pro-survival functions involve differential interactions with caspase-3. J Biol Chem. 282:31289–31301. 2007. View Article : Google Scholar : PubMed/NCBI
14	Ghosh JC, Dohi T, Kang BH and Altieri DC: Hsp60 regulation of tumor cell apoptosis. J Biol Chem. 283:5188–5194. 2008. View Article : Google Scholar
15	Kaigorodova EV and Bogatyuk MV: Heat shock proteins as prognostic markers of cancer. Curr Cancer Drug Targets. 14:713–726. 2014. View Article : Google Scholar : PubMed/NCBI
16	Lee JH, Cho HS, Lee JJ, Jun SY, Ahn JH, Min JS, Yoon JY, Choi MH, Jeon SJ, Lim JH, et al: Plasma glutamate carboxypeptidase is a negative regulator in liver cancer metastasis. Oncotarget. 7:79774–79786. 2016. View Article : Google Scholar : PubMed/NCBI
17	Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, et al TCGA Research Network: Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell. 163:506–519. 2015. View Article : Google Scholar : PubMed/NCBI
18	Jung KB, Lee H, Son YS, Lee JH, Cho HS, Lee MO, Oh JH, Lee J, Kim S, Jung CR, et al: In vitro and in vivo imaging and tracking of intestinal organoids from human induced pluripotent stem cells. FASEB J. 32:111–122. 2018. View Article : Google Scholar
19	Jung KB, Lee H, Son YS, Lee MO, Kim YD, Oh SJ, Kwon O, Cho S, Cho HS, Kim DS, et al: Interleukin-2 induces the in vitro maturation of human pluripotent stem cell-derived intestinal organoids. Nat Commun. 9:30392018. View Article : Google Scholar : PubMed/NCBI
20	Kim DS, Ryu JW, Son MY, Oh JH, Chung KS, Lee S, Lee JJ, Ahn JH, Min JS, Ahn J, et al: A liver-specific gene expression panel predicts the differentiation status of in vitro hepatocyte models. Hepatology. 66:1662–1674. 2017. View Article : Google Scholar : PubMed/NCBI
21	Son MY, Jung CR, Kim DS and Cho HS: Comparative in silico profiling of epigenetic modifiers in human tissues. Mol Biol Rep. 45:309–314. 2018. View Article : Google Scholar : PubMed/NCBI
22	Ryu JW, Kim SK, Son MY, Jeon SJ, Oh JH, Lim JH, Cho S, Jung CR, Hamamoto R, Kim DS, et al: Novel prognostic marker PRMT1 regulates cell growth via downregulation of CDKN1A in HCC. Oncotarget. 8:115444–115455. 2017. View Article : Google Scholar
23	Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, et al Cancer Genome Atlas Research Network: An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell. 173:400–416.e11. 2018. View Article : Google Scholar : PubMed/NCBI
24	Arya RK, Singh A, Yadav NK, Cheruvu SH, Hossain Z, Meena S, Maheshwari S, Singh AK, Shahab U, Sharma C, et al: Anti-breast tumor activity of Eclipta extract in-vitro and in-vivo: Novel evidence of endoplasmic reticulum specific localization of Hsp60 during apoptosis. Sci Rep. 5:184572015. View Article : Google Scholar : PubMed/NCBI
25	Chang Y, Zhang X, Horton JR, Upadhyay AK, Spannhoff A, Liu J, Snyder JP, Bedford MT and Cheng X: Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat Struct Mol Biol. 16:312–317. 2009. View Article : Google Scholar : PubMed/NCBI
26	Lebret T, Watson RW, Molinié V, O’Neill A, Gabriel C, Fitzpatrick JM and Botto H: Heat shock proteins HSP27, HSP60, HSP70, and HSP90: Expression in bladder carcinoma. Cancer. 98:970–977. 2003. View Article : Google Scholar : PubMed/NCBI
27	Cho HS, Shimazu T, Toyokawa G, Daigo Y, Maehara Y, Hayami S, Ito A, Masuda K, Ikawa N, Field HI, et al: Enhanced HSP70 lysine methylation promotes proliferation of cancer cells through activation of Aurora kinase B. Nat Commun. 3:10722012. View Article : Google Scholar : PubMed/NCBI